START-001: what clinicians are saying
invikafusp alfa (STAR0602); invikafusp alfa (STAR0602) plus irinotecan; invikafusp alfa (STAR0602) plus docetaxel in antigen-rich advanced solid tumors · NCT05592626 ↗ · Phase 1/Phase 2 · Marengo Therapeutics, Inc.
A physician reads START-001 favorably because of activity after checkpoint-inhibitor failure, but stresses that the evidence is preliminary. A speaker's stronger endorsement concerns TMB-high colorectal cancer without liver metastases; another cautions against treating activity as established benefit, citing small numbers. Cytokine-release syndrome remains a concern in the discussion. Durability is unresolved, and results from different dose and biomarker groups cannot be treated as a single response estimate.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 66 verified statements
This edition $750, with MCP access for your AI agent. Get this report
7 findings, and what sits behind each
01. START-001: what most speakers highlight in preliminary activity in refractory tumors
4 of the report's 5 cited clinicians · 22 statements from 9 speakers in 15 sources, 3 of them podcasts or videos · 20 passages
Limitations recorded: 4.
Draws on: Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR), Population and setting, Secondary endpoints, Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Safety and tolerability.
02. Early transient AEs: what some clinicians highlight, but some speakers flag CRS risk
3 of the report's 5 cited clinicians · 7 statements from 5 speakers in 7 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 4.
Draws on: Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Safety and tolerability, Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR), Secondary endpoints, Population and setting.
03. Trial access: what speakers say
2 of the report's 5 cited clinicians · 6 statements from 4 speakers in 6 sources · 8 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, The comparison.
04. Immune-cold tumors: what speakers say
4 of the report's 5 cited clinicians · 8 statements from 4 speakers in 6 sources, 1 of them a podcast or video · 9 passages
Limitations recorded: 3.
Draws on: Population and setting, Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR), Secondary endpoints.
05. T-cell selectivity: what speakers stress; a clinician ties RP2D to expansion
3 of the report's 5 cited clinicians · 11 statements from 4 speakers in 6 sources, 1 of them a podcast or video · 13 passages
Limitations recorded: 3.
Draws on: The comparison, Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1, Population and setting.
06. Invikafusp alfa: why a speaker favors it on a hunch and a scan example
No named clinician · accounts and unnamed speakers · 5 statements from 2 speakers in 1 source · 3 passages
Limitations recorded: 3.
Draws on: Secondary endpoints.
Beyond the trial population
07. Preclinical T-cell reprogramming: why a clinician supports clinical testing
2 of the report's 5 cited clinicians · 15 statements from 2 speakers in 3 sources · 19 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 7
4 of the report's 5 cited clinicians
START-001: what most speakers highlight in preliminary activity in refractory tumors
22 statements from 9 speakers in 15 sources, 3 of them podcasts or videos
8 of the 9 named speakers in this finding hold this view
- 22
- statements
- 20
- passages
- 15
- sources
- 9
- speakers
What the statements areViews 16Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 5Statement-to-passage links (a passage can back several statements)Supporting a statement 25Giving context 1Recorded with the findingLimitations: 4
10 posts and articles · 3 podcasts and video · 2 publications
Draws on: Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR), Population and setting, Secondary endpoints, Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Safety and tolerability.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 7 findings and 15 of the 66 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (10)
AE, adverse event; CRS, cytokine release syndrome; DLT, dose-limiting toxicity; FDA, US Food and Drug Administration; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; RP2D, recommended phase 2 dose; SAE, serious adverse event.
The full START-001 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 52commentary sources screened
- 20sources cited by verified statements
- 13named in screened sources
- 13speakers cited in the report
- 8cited speakers with a verified identity
5 cited clinicians, speakers with a confirmed clinical role, of them 5 physicians. By role and specialty:
- 3 physician, specialty not confirmed
- 1 physician, Gastroenterology
- 1 physician, Medical oncology
Also in the sources: 1 organizational or shared account, not counted as people.
- 66verified statements, each linked to its source
- 40of them from speakers with a confirmed clinical role
- 7findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 66 | Paid |
| Who said each statement: the cited speakers | 13 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 5 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 20 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
12 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1 | 1 | 1 |
| Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | 5 | 5 |
| Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR) | 15 | 12 |
| Secondary endpoints | 8 | 6 |
| Population and setting | 13 | 10 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 2 | 2 |
| Safety and tolerability | 5 | 5 |
| Design and conductno commentary found | 0 | 0 |
| Selective signaling and biological dose selection | 8 | 4 |
| Baseline predictors and treatment-induced immune changes | 6 | 4 |
| Research access, patient support and regulatory expectations | 6 | 5 |
| Anecdotal comparison with Anktiva in metastatic disease | 5 | 1 |
| Preclinical rationale and proposed immune reprogramming | 15 | 3 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
66 verified statements from 20 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 10 statements · 15% | ||||
| YouTube | 10 | 3 | 3 | |
| Posts · 48 statements · 73% | ||||
| X threads | 48 | 15 | 46 | |
| LinkedIn posts | 0 | 0 | 2 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 8 statements · 12%cited for context, not screened | ||||
| Publications | 8 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 12 / quarter
- Screened window
- Oct 28, 2022 → Oct 31, 2026
- Cited window
- Nov 10, 2022 → Oct 31, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
- Registry
- NCT05592626
- Study IDs
- CP-START-001 · 2023-505334-10-01
- Sponsor
- Marengo Therapeutics, Inc.
- Design
- Phase 1/Phase 2 · Interventional, non randomized, sequential
- Status
- Recruiting
- Enrollment
- 366 estimated
- Registered
- 2022-10-24
- Start
- 2023-01-04 actual
- Primary completion
- 2027-09 estimated
- Primary endpoints
- Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1
- Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)
- Interventions
- 3 registered
More on: Advanced solid tumors, Non-small cell lung cancer, Colorectal cancer, irinotecan, docetaxel
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 33 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 25 sources about other trials or topics are not included.
- Repeated posts, reposts, presentation summaries and near-identical interview extracts should not be counted as independent HCP assessments.
- Several favorable views come from people described by their sources as involved in START-001 or STAR0602 development; those descriptions do not establish independent external endorsement.
Show all 10 known gaps +Fewer −
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The accounts use different phases, dose subsets, biomarker groups and outcome definitions. Percentages cannot be pooled, and target-lesion regression must not be relabeled as objective response or disease control.
- Small patient numbers and uncertain durability limit the strength of the clinical-benefit interpretation, even where speakers are enthusiastic.
- No trial protocol or matching regulatory label was available in the reviewed material. Detailed supportive-care rules and the X exchange's FDA-approval assertion could not be independently checked.
- The access and referral statements are dated experiences, not confirmation of current site availability or individual eligibility. A speaker's cancer type is not stated.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. START-001 (NCT05592626): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/start-001-nct05592626
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "START-001" (NCT05592626), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "start-001-nct05592626". If you cannot make requests, read https://www.erudio.com/reports/start-001-nct05592626.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05592626", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05592626 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/start-001-nct05592626.json
curl https://www.erudio.com/reports/start-001-nct05592626.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "start-001-nct05592626" })release e2024c46f4598f6ec53a03ed10612732e9b12ba4349af392bdfaf5bcb0537c28
Questions
How much does the START-001 report cost?
One edition costs $750 (Focused · 66 verified statements · 40 from 5 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the START-001 report cover?
66 statements from 20 sources (3 videos, 15 posts, 2 papers), 40 of them from 5 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the START-001 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "start-001-nct05592626" }) previews it and create_order({ "report": "start-001-nct05592626", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the START-001 report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.